A5052085580- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Bone Tumor Diagnosis and Treatments
- Metastasis and carcinoma case studies
- RNA Interference and Gene Delivery
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Soft tissue tumor case studies
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer Research and Treatments
- Hematological disorders and diagnostics
- Cancer Mechanisms and Therapy
- Gastrointestinal disorders and treatments
University of Turin
2014-2025
Ospedale San Luigi Gonzaga
2022-2025
Candiolo Cancer Institute
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2024
Media Working Group
2024
National Cancer Institute
2022
Azienda Ospedaliera S.Maria
2022
Azienda Sanitaria Locale di Asti
2021
Ospedale Sant'Anna
2013
Istituto Ortopedico Rizzoli
2013
Background Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity PD-1 inhibitors. A potential strategy convert a cold into an inflamed microenvironment lies on combination therapy. As tumor angiogenesis promotes immunosuppression, we designed phase Ib/II trial test double inhibition (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods This single-arm, enrolled adult patients with selected subtypes sarcoma. Phase Ib established two dose...
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, ifosfamide, and alone as first-line treatments advanced/metastatic treated at European Organization Research Treatment of Cancer Soft Tissue Bone Sarcoma Group (EORTC-STBSG) sites.The inclusion criteria were a confirmed histological diagnosis, between January 2010 December 2015, measurable disease...
The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, sorafenib-treated patients with metastatic-relapsed osteosarcoma, disease stabilization and tumor shrinkage were short-lived drug resistance occurred. We explored the treatment escape mechanisms to overcome their drawbacks.Immunoprecipitation, Western blotting, immunohistochemistry used analyze mTOR pathway [mTOR complex 1 (mTORC1) 2 (mTORC2)]. Cell viability, colony growth, cell...
Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability eradicate chemoresistant cancer stem-like cells (sCSC) that likely responsible for relapses drug resistance. In this study, we investigated preclinical activity of patient-derived cytokine-induced killer (CIK) against autologous STS, including putative sCSCs. Tumor killing was evaluated both in vitro within an immunodeficient mouse model sarcoma. To identify sCSCs, STS were engineered with...
Enhancing the antitumor activity of DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin isoquinoline alkylating agent with a peculiar mechanism action. It binds minor groove DNA inducing single- and double-strand-breaks. These kinds damage lead activation PARP1, first-line enzyme in DNA-damage response pathways. We hypothesized that PARP1 targeting could perpetuate trabectedin-induced tumor cells leading finally cell death.We investigated...
Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for many hematologic malignancies but it is limited by high nonrelapse mortality (NRM), primarily from unpredictable control of graft-versus-host disease (GVHD). Recently, post-transplant cyclophosphamide demonstrated improved GVHD in allogeneic bone marrow HCT. Here we explore peripheral blood stem transplantation (alloPBSCT). Patients with high-risk received alloPBSCT HLA-matched unrelated/related donors....
Background: Data on temozolomide (TEM) and irinotecan (IRI) activity in recurrent Ewing sarcoma (EWS), especially adult patients, are limited.Methods: Patients receiving TEM 100 mg/m2/day oral, IRI 40 intravenous, days 1–5, every 21 days, were included this multi-institutional retrospective study. Disease control rate (DCR) [overall response (ORR) [complete (CR) + partial (PR)] stable disease (SD)], 6-months progression-free survival (6-mos PFS) 1-year overall (OS) assessed.Results: The...
Abstract Background Immune checkpoint blockade (ICB) has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients, although most patients develop mechanisms resistance. Recently single-cell RNA-sequencing (scRNA-Seq) revealed a huge T-cell phenotypic and (dys)functional state variability. Accordingly, exhaustion is recognized as functional adaptation, with dynamic progression from long-lived “pre-exhausted stem-like progenitor” to “terminally exhausted” state. In this...
Importance The D842V platelet-derived growth factor receptor α ( PDGFRA ) mutation identifies a molecular subgroup of gastrointestinal stromal tumors (GISTs), primarily resistant to standard tyrosine kinase inhibitors and with an overall more indolent behavior. Although functional imaging 18 F-fluorodeoxyglucose–labeled positron emission tomography ([ F]FDG-PET) plays proven role in GISTs, especially early assessment tumor response, less is known about [ F]FDG uptake according the GIST...
Abstract From 17 to 19th October 2024, the XXI Italian Network for Bio-Immunotherapy of Tumors Meeting (NIBIT) took place in Palermo, marvelous historical location Teatro Politeama, under auspices Association Medical Oncology (AIOM), Cancer Research (AIRC), Fondazione Pezcoller, Alliance against (ACC), Lymphoma Foundation (FIL), Grazia Focacci and Melagioco Foundation. The conference covered a spectrum topics ranging from target discovery therapeutic advances immuno-oncology, bringing...
No effective therapy is available for unresectable soft-tissue sarcomas (STS). This unmet clinical need prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CAR.CIK) are in eliminating tumor cells derived from multiple STS histotypes vitro and immunodeficient mice.The experimental platform included patient-derived CAR.CIK cell lines established histotypes. were transduced with a...
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) practice guidelines for sarcoma treatment are applicable AS, its unique aggressiveness diverse tumor presentations necessitate dedicated detailed recommendations, which currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), neoadjuvant/adjuvant...